Gasbarrini, Nadia
Dubravić, Davor
Combs, Lauren
Dišković, Arian
Ankiersztejn-Bartczak, Magdalena
Colaiaco, Francesca
Wawer, Iwona
Wysocki, Piotr
Rosińska, Magdalena
Marzec-Boguslawska, Anna
Collins, Ben
Simões, Daniel
Jakobsen, Marie Louise
Raben, Dorthe
Funding for this research was provided by:
Third Health Programme of the European Union (761319)
Gilead Sciences (03976)
ViiV Healthcare
Janssen Pharmaceuticals
Merck
City of Zagreb - Croatia, cooperation programmes
Ministry of Health, Croatia, cooperation programmes
Cepheid
Department of Immunological and Molecular Diagnostics of the Clinic for Infectious Diseases Dr Fran Mihaljević
Health Department of Lazio Regional Administration of Italy
Fundação para a Ciência e Tecnologia (PD/BD/128008/2016)
Article History
Received: 3 August 2021
Accepted: 6 August 2021
First Online: 13 September 2021
Declarations
:
: All pilots are established testing sites and no specific ethical approval was required for the additional pilot testing activities. By standard procedure, all clients gave their consent to participate in testing activities and data collection in all pilot activities in Croatia, Italy and Poland, all according to GDPR regulations.
: Not applicable.
: There are no competing interests to be reported by all authors.